NCT01374984View on ClinicalTrials.gov

VA-005 Clinical Outcomes of VIGIV Treatment of Smallpox Vaccination Complications or Vaccinia Infection

Enrolling by invitationOBSERVATIONAL
Enrollment

100

Participants

Timeline

Start Date

August 31, 2007

Primary Completion Date

August 31, 2026

Study Completion Date

August 31, 2027

Conditions
Complication of Smallpox Vaccination
Interventions
BIOLOGICAL

VIGIV

VIGIV is licensed in US, by the FDA, for the treatment of complications of smallpox vaccinations and is available to eligible patients regardless of participation in this study.

Sponsors
All Listed Sponsors
collaborator

Centers for Disease Control and Prevention

FED

lead

Emergent BioSolutions

INDUSTRY